title: Glucose infusion causes insulin resistance in skeletal muscle of rats without changes in Akt and AS160 phosphorylation.
abstract: Hyperglycemia is a defining feature of Type 1 and 2 diabetes. Hyperglycemia also causes insulin resistance, and our group (Kraegen EW, Saha AK, Preston E, Wilks D, Hoy AJ, Cooney GJ, Ruderman NB. Am J Physiol Endocrinol Metab Endocrinol Metab 290: E471-E479, 2006) has recently demonstrated that hyperglycemia generated by glucose infusion results in insulin resistance after 5 h but not after 3 h. The aim of this study was to investigate possible mechanism(s) by which glucose infusion causes insulin resistance in skeletal muscle and in particular to examine whether this was associated with changes in insulin signaling. Hyperglycemia (~10 mM) was produced in cannulated male Wistar rats for up to 5 h. The glucose infusion rate required to maintain this hyperglycemia progressively lessened over 5 h (by 25%, P < 0.0001 at 5 h) without any alteration in plasma insulin levels consistent with the development of insulin resistance. Muscle glucose uptake in vivo (44%; P < 0.05) and glycogen synthesis rate (52%; P < 0.001) were reduced after 5 h compared with after 3 h of infusion. Despite these changes, there was no decrease in the phosphorylation state of multiple insulin signaling intermediates [insulin receptor, Akt, AS160 (Akt substrate of 160 kDa), glycogen synthase kinase-3beta] over the same time course. In isolated soleus strips taken from control or 1- or 5-h glucose-infused animals, insulin-stimulated 2-deoxyglucose transport was similar, but glycogen synthesis was significantly reduced in the 5-h muscle sample (68% vs. 1-h sample; P < 0.001). These results suggest that the reduced muscle glucose uptake in rats after 5 h of acute hyperglycemia is due more to the metabolic effects of excess glycogen storage than to a defect in insulin signaling or glucose transport.
authors.affiliation: Diabetes and Obesity Research Program, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.
authors.forename: Andrew J
authors.initials: AJ
authors.lastname: Hoy
authors.forename: Clinton R
authors.initials: CR
authors.lastname: Bruce
authors.forename: Anna
authors.initials: A
authors.lastname: Cederberg
authors.forename: Nigel
authors.initials: N
authors.lastname: Turner
authors.forename: David E
authors.initials: DE
authors.lastname: James
authors.forename: Gregory J
authors.initials: GJ
authors.lastname: Cooney
authors.forename: Edward W
authors.initials: EW
authors.lastname: Kraegen
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D020690:GTPase-Activating Proteins / Q000378:metabolism*; D005947:Glucose / Q000008:administration & dosage* / Q000378:metabolism; D006003:Glycogen / Q000378:metabolism; D006943:Hyperglycemia / Q000378:metabolism*; D066298:In Vitro Techniques; D007262:Infusions, Intravenous; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance / Q000502:physiology*; D008297:Male; D018482:Muscle, Skeletal / Q000378:metabolism*; D051058:Oncogene Protein v-akt / Q000378:metabolism*; D010766:Phosphorylation; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D015398:Signal Transduction